Pulnovo Medical Secures $100 Million Funding with Investment from Medtronic
Pulnovo Medical, a leader in innovative therapies for treating pulmonary hypertension and heart failure, has recently announced a significant milestone in its growth journey. The company has successfully closed an oversubscribed financing round, raising $100 million, with a prominent investment from Medtronic, a global leader in medical technologies. This milestone reflects strong validation for Pulnovo's pioneering technology and its clinical advancements in combating serious cardiopulmonary diseases.
The financing round also saw continued backing from existing investors such as EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures, alongside new entrants like HSG, enhancing its investor roster. This funding is intended to bolster Pulnovo's commercialization efforts in vital regions including the European Union, Middle East, and China, alongside ongoing clinical development and regulatory submissions.
Pulnovo's flagship product, the Pulmonary Artery Denervation (PADN) System, is a first-of-its-kind minimally invasive therapy designed to alleviate overactive sympathetic nerve activity, a significant contributory factor in cardiopulmonary conditions. The company has conducted around 1,500 PADN procedures worldwide and has achieved regulatory approvals across seven countries. The FDA has also recognized the device by granting it a Breakthrough Device designation, which streamlines its regulatory pathway in the U.S.
In terms of clinical progress, Pulnovo's recent commercial agreement with Medtronic has opened avenues for future partnerships focused on enhancing their joint capabilities, leveraging Medtronic's extensive global reach in medical commercialization. Medtronic’s investment not only provides capital but also signifies confidence in Pulnovo's vision and its transformative technology in improving patient outcomes.
Cynthia Chen, Chairlady and President of Pulnovo Medical, expressed. "This financing marks a strategic transition into a fully integrated global platform that pivots our focus from being product-driven to enhancing scalability through innovation and partnerships. We're excited about the potential our collaboration with Medtronic brings to further our clinical and technological advancements..."
In a bid to expand its leadership team, Pulnovo has welcomed Andre Xiao as the Chief Strategy Officer. With a wealth of experience in healthcare investment from distinguished firms such as Citadel and Millennium Management, he will spearhead efforts to elevate the firm's strategies, finance approaches, and market outreach.
The PADN System's progress has been notable, showing promising clinical outcomes that have resulted in its inclusion in major international clinical guidelines, validating its efficacy in managing pulmonary hypertension. With clinical trials currently underway across Europe and Asia, Pulnovo aims to validate its standing as a leader in providing innovative solutions for cardiopulmonary conditions, addressing significant unmet needs in patient care.
Overall, this $100 million financing not only represents a boost for Pulnovo Medical's operational capabilities but also showcases the trust placed by leading strategic and institutional investors in Pulnovo's long-term vision. As the company pioneers innovative approaches in treating cardiopulmonary diseases, the expectation is high for their solutions to bring meaningful changes in the lives of patients around the globe.
The financing round also saw continued backing from existing investors such as EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures, alongside new entrants like HSG, enhancing its investor roster. This funding is intended to bolster Pulnovo's commercialization efforts in vital regions including the European Union, Middle East, and China, alongside ongoing clinical development and regulatory submissions.
Pulnovo's flagship product, the Pulmonary Artery Denervation (PADN) System, is a first-of-its-kind minimally invasive therapy designed to alleviate overactive sympathetic nerve activity, a significant contributory factor in cardiopulmonary conditions. The company has conducted around 1,500 PADN procedures worldwide and has achieved regulatory approvals across seven countries. The FDA has also recognized the device by granting it a Breakthrough Device designation, which streamlines its regulatory pathway in the U.S.
In terms of clinical progress, Pulnovo's recent commercial agreement with Medtronic has opened avenues for future partnerships focused on enhancing their joint capabilities, leveraging Medtronic's extensive global reach in medical commercialization. Medtronic’s investment not only provides capital but also signifies confidence in Pulnovo's vision and its transformative technology in improving patient outcomes.
Cynthia Chen, Chairlady and President of Pulnovo Medical, expressed. "This financing marks a strategic transition into a fully integrated global platform that pivots our focus from being product-driven to enhancing scalability through innovation and partnerships. We're excited about the potential our collaboration with Medtronic brings to further our clinical and technological advancements..."
In a bid to expand its leadership team, Pulnovo has welcomed Andre Xiao as the Chief Strategy Officer. With a wealth of experience in healthcare investment from distinguished firms such as Citadel and Millennium Management, he will spearhead efforts to elevate the firm's strategies, finance approaches, and market outreach.
The PADN System's progress has been notable, showing promising clinical outcomes that have resulted in its inclusion in major international clinical guidelines, validating its efficacy in managing pulmonary hypertension. With clinical trials currently underway across Europe and Asia, Pulnovo aims to validate its standing as a leader in providing innovative solutions for cardiopulmonary conditions, addressing significant unmet needs in patient care.
Overall, this $100 million financing not only represents a boost for Pulnovo Medical's operational capabilities but also showcases the trust placed by leading strategic and institutional investors in Pulnovo's long-term vision. As the company pioneers innovative approaches in treating cardiopulmonary diseases, the expectation is high for their solutions to bring meaningful changes in the lives of patients around the globe.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.